Anavex Life Sciences (AVXL) to Release Earnings on Tuesday
by Scott Moore · The Cerbat GemAnavex Life Sciences (NASDAQ:AVXL – Get Free Report) is projected to announce its Q2 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:30 AM ET.
Anavex Life Sciences (NASDAQ:AVXL – Get Free Report) last issued its quarterly earnings results on Monday, February 9th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.04. On average, analysts expect Anavex Life Sciences to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Anavex Life Sciences Stock Down 2.1%
Anavex Life Sciences stock traded down $0.07 during trading on Tuesday, reaching $3.34. The stock had a trading volume of 231,942 shares, compared to its average volume of 1,406,132. Anavex Life Sciences has a 52-week low of $2.61 and a 52-week high of $13.99. The business has a 50 day moving average price of $3.78 and a 200 day moving average price of $4.61. The stock has a market cap of $309.52 million, a PE ratio of -7.26 and a beta of 1.24.
Analyst Ratings Changes
AVXL has been the subject of a number of recent research reports. Rodman & Renshaw initiated coverage on shares of Anavex Life Sciences in a research note on Monday. They issued a “buy” rating and a $20.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Anavex Life Sciences in a research note on Tuesday, February 10th. Wall Street Zen upgraded shares of Anavex Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th. D. Boral Capital reiterated a “buy” rating and issued a $24.00 price target on shares of Anavex Life Sciences in a research note on Tuesday, March 31st. Finally, Weiss Ratings upgraded shares of Anavex Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 22nd. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $21.33.
Check Out Our Latest Stock Report on AVXL
Hedge Funds Weigh In On Anavex Life Sciences
A number of institutional investors have recently modified their holdings of AVXL. State of Wyoming acquired a new position in shares of Anavex Life Sciences in the 2nd quarter valued at $26,000. Quarry LP acquired a new position in shares of Anavex Life Sciences in the 3rd quarter valued at $36,000. Aigen Investment Management LP acquired a new position in Anavex Life Sciences in the 4th quarter valued at $44,000. Integrated Wealth Concepts LLC acquired a new position in Anavex Life Sciences in the 4th quarter valued at $46,000. Finally, Russell Investments Group Ltd. increased its stake in Anavex Life Sciences by 11,540.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,984 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 6,924 shares during the period. 31.55% of the stock is owned by institutional investors and hedge funds.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.
The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.